Last reviewed · How we verify
L-carnitine L-tartrate
At a glance
| Generic name | L-carnitine L-tartrate |
|---|---|
| Sponsor | HealthPartners Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Plasma Trimethylamine N-oxide Elevation Induced by L-carnitine Supplementation and Insulin Resistance (NA)
- L-Carnitine Protective Effect in Nephrotoxicity (PHASE2)
- 12-Week Trial Investigating L-carnitine Tartrate, Dihydrocapsiate and Protein Yeast Hydrolysate on Energy Intake and Expenditure in Overweight Adults (NA)
- Assessment of the Efficacy of Carnipure® AAS on Body Composition, Muscle Thickness, and Strength Adaptations in Healthy Men (NA)
- Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients (PHASE2, PHASE3)
- Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease (PHASE2)
- A Single-Group Study to Examine the Efficacy of a Gut Health Supplement to Increase Metabolism, Improve Gut Health, and Support Weight Management (NA)
- L-carnitine Supplementation in Rheumatoid Arthritis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-carnitine L-tartrate CI brief — competitive landscape report
- L-carnitine L-tartrate updates RSS · CI watch RSS
- HealthPartners Institute portfolio CI